Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab plus topical corticosteroids in cyclosporine-ineligible or cyclosporine-inadequately controlled moderate-to-severe atopic dermatitis
NL-OMON52148Phase 3Not yet recruiting
- Sponsor
- Almirall
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Lebrikizumab + topical corticosteroids with Placebo + topical corticosteroids (2 arms). Primary endpoint: EASI 75 at Week 16. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON52148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52148.